Skip to main content
CELC
NASDAQ Life Sciences

FDA Approves Celcuity's REVTORPYK for Breast Cancer, Launch Set for Late Q3

Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$106
Mkt Cap
$5.415B
52W Low
$13.365
52W High
$151.02
52W Position info
693% above low
Off High info
30% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

CELC has more than doubled off its 52-week low of $13.365.

Summary

The FDA approved Celcuity's REVTORPYK (gedatolisib) for HR+/HER2- metastatic breast cancer without a PIK3CA mutation, following yesterday's initial approval report. The drug showed a 76% reduction in progression/death risk in the triplet regimen, with median PFS of 9.3 vs 2.0 months. Celcuity plans a late Q3 commercial launch and will submit an sNDA in Q3 for the PIK3CA-mutant cohort. This approval validates the company's lead asset and opens a significant market opportunity, though the stock already reacted sharply to the news yesterday.

At the time of this announcement, CELC was trading at $106.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $13.37 to $151.02. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

CELC - Latest Insights

CELC
Nov 09, 2026, 8:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $66.32
Real-time Price: $64.37 info
Change: -$1.95 (-3%) info
Market Cap: $3.162B info
CELC
Nov 05, 2026, 5:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $64.37 info
Change: +$0.330 (+0.52%) info
Market Cap: $3.162B info
CELC
Nov 05, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $64.37 info
Change: +$0.330 (+0.52%) info
Market Cap: $3.162B info
CELC
Nov 05, 2026, 4:02 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $64.37 info
Change: +$0.330 (+0.52%) info
Market Cap: $3.162B info
CELC
Sep 30, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $79.00
Real-time Price: $64.37 info
Change: -$14.63 (-19%) info
Market Cap: $3.162B info